bendamustine hydrochloride has been researched along with Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masuda, S; Uchida, M; Watanabe, H | 1 |
| Brakhage, A; Cheson, BD; Herold, M; Leoni, L; Merkle, K; Ruffert, K; Werner, W | 1 |
| Adamopoulos, AM; Falchook, GS; Fortier, A; Fu, S; Hess, KR; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Ye, Y | 1 |
| Gidwani, B; Vyas, A | 1 |
| Huang, P; Shi, L; Su, Y; Yan, D; Zhang, T; Zhou, L; Zhu, X | 1 |
| Apostolopoulos, C; Castellano, L; Giamas, G; Stebbing, J | 1 |
| Cheson, BD; Rummel, MJ | 1 |
| Masiello, D; Tulpule, A | 1 |
| Bischofs, E; Eichbaum, M; Nehls, K; Schneeweiss, A; Sohn, C | 1 |
| Ding, R; Feng, M; He, Y; Li, G; Liu, H; Peng, C; Qi, C; Wang, M; Wang, X; Xu, J; Zhang, S | 1 |
| Beijnen, JH; Darwish, M; Dubbelman, AC; Hellriegel, E; Jansen, RS; Robertson, P; Rosing, H; Schellens, JH | 1 |
| Hartley, JA; Hochhauser, D | 1 |
| Beijnen, JH; Bond, M; D'Andrea, D; Darwish, M; Dubbelman, AC; Hellriegel, E; Robertson, P; Rosing, H; Schellens, JH | 1 |
| Bosmans, J; Dyck, J; Merkle, K; Rasschaert, M; Schrijvers, D; Van den Brande, J; Vermorken, JB | 2 |
| Ganser, A; Grünwald, V; Hagedorn, T; Kowalski, R; Merkle, K; Paul, H; Schöffski, P | 1 |
| Engel, H; Ganser, A; Grünwald, V; Kowalski, R; Merkle, K; Paul, H; Schöffski, P; Seeland, G | 1 |
5 review(s) available for bendamustine hydrochloride and Neoplasms
| Article | Year |
|---|---|
[Clinical Pharmacology Research for Promoting Individualized Cancer Chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Nausea; Neoplasms; Pharmacology, Clinical; Precision Medicine; Quality of Health Care; Research | 2019 |
Bendamustine as a model for the activity of alkylating agents.
Topics: Alkylating Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Models, Biological; Neoplasms; Nitrogen Mustard Compounds | 2008 |
Bendamustine: rebirth of an old drug.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Neoplasms; Nitrogen Mustard Compounds | 2009 |
Bendamustine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Drug Tolerance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Nitrogen Mustard Compounds | 2009 |
Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzodiazepinones; Dioxoles; DNA; DNA Damage; Humans; Neoplasms; Nitrogen Mustard Compounds; Pyrroles; Tetrahydroisoquinolines; Trabectedin | 2012 |
6 trial(s) available for bendamustine hydrochloride and Neoplasms
| Article | Year |
|---|---|
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Treatment Outcome; Young Adult | 2014 |
Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carbon Radioisotopes; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Nitrogen Mustard Compounds; Recurrence | 2013 |
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds | 2007 |
A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Treatment Outcome | 2007 |
Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Patient Selection; Treatment Outcome | 2000 |
Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Topics: Adult; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Life Expectancy; Lymphocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Nitrogen Mustard Compounds | 2000 |
6 other study(ies) available for bendamustine hydrochloride and Neoplasms
| Article | Year |
|---|---|
[Developmental history: bendamustine yesterday, today, tomorrow].
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Industry; History, 20th Century; History, 21st Century; Humans; Neoplasms; Nitrogen Mustard Compounds | 2013 |
Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment.
Topics: Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclodextrins; Drug Carriers; Drug Delivery Systems; Freeze Drying; Humans; Lactic Acid; Nanospheres; Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility | 2016 |
Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Floxuridine; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Nanoparticles; Neoplasms | 2015 |
Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.
Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Neoplasms; Nitrogen Mustard Compounds | 2009 |
(18)F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Benzimidazoles; Chromatography, High Pressure Liquid; Female; Fluorine Radioisotopes; Indicators and Reagents; Isotope Labeling; Mice; Neoplasms; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma 180; Solubility; Solvents; Tissue Distribution | 2010 |
Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carbon Radioisotopes; Creatinine; Cysteine; Dealkylation; Humans; Hydrolysis; Hydroxylation; Metabolic Networks and Pathways; Metabolome; Neoplasms; Nitrogen Mustard Compounds; Oxidation-Reduction; Phosphates; Uric Acid | 2012 |